Stockscreener 앱 받기
12.78
1.46%
-0.19
시간 외 거래:
12.76
-0.02
-0.16%
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 - Investing.com
Candel Therapeutics to Present at September Investor Conferences - Moomoo
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Hits New 1-Year HighHere's Why - MarketBeat
Candel Therapeutics CTO Seshu Tyagarajan Executes 7,000-Share Sale Under 10b5-1 Plan - Kalkine Media
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up - tradingview.com
Research Analysts Set Expectations for CADL Q3 Earnings - MarketBeat
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets - MarketBeat
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
(CADL) Risk Channels and Responsive Allocation - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $23 - Moomoo
Stifel Nicolaus Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics (CADL) Receives a Hold from Bank of America Securities - The Globe and Mail
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss - MarketBeat
Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside - TradingView
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 - Moomoo
Equities Analysts Offer Predictions for CADL FY2028 Earnings - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $25 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics grants stock options to new Chief Commercial Officer - scanx.trade
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - TradingView
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month HighHere's What Happened - MarketBeat
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Q2 EPS of $(0.52) misses estimates - scanx.trade
Candel Therapeutics Reports Q2 2026 Financials and Pipeline Progress in SEC Form 10-Q - Kalkine Media
Candel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Candel Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Candel Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss - marketscreener.com
Candel Therapeutics, Inc. Q2 2026: Net income $(38.9M), EPS $(0.52) — 10-Q Summary - TradingView
Candel Therapeutics (NASDAQ: CADL) widens H1 2026 loss while boosting cash above $200M - Stock Titan
0.86%
0.31%
자본화:
|
볼륨(24시간):